Status:
COMPLETED
Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer
Lead Sponsor:
Institut Cancerologie de l'Ouest
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Neoadjuvant chemotherapy (NAC) is frequently proposed to patients with large tumours that can be operated in order to increase the chances of breast conservation. After NAC, patients are operated with...
Eligibility Criteria
Inclusion
- T2-T3 operable infiltrating breast carcinoma
- No allergy to Patent Blue
- Pre-operative diagnosis of unifocal infiltrating breast carcinoma.
- Patient planned to be treated by NAC.
- Informed consent.
- Surgery available 4 to 6 weeks after the last chemotherapy course (radical or conservative surgery)
Exclusion
- pT4d (inflammatory breast cancer)
- Locally advanced or metastatic breast cancer
- Any previous chemotherapy of contra-lateral breast cancer.
- Breast cancer local relapse
- Previous surgical removal of breast Cancer.
- Inadequate biopsy for pathological analysis.
- Dementia or altered mental disorder
- Pregnant woman or breast feeding or without efficacious contraceptive method.
- Contra-indication to NAC NAC interrupted due to progressive disease.
- Neoadjuvant radiotherapy.
Key Trial Info
Start Date :
July 12 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2019
Estimated Enrollment :
958 Patients enrolled
Trial Details
Trial ID
NCT01221688
Start Date
July 12 2010
End Date
December 10 2019
Last Update
April 25 2022
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU
Angers, France, 49 933
2
Institut de Cancerologie de L'Ouest
Angers, France, 49055
3
Institut Bergonié
Bordeaux, France, 33000
4
CHU
Brest, France, 29609